^
Association details:
| Biomarker: | MDM2 mutation |
|---|---|
| Cancer: | Non Small Cell Lung Cancer |
| Drug Class: | Immunotherapy |
| Direction: | Resistant |
Evidence:
Source:
Title:
Genomic markers associated with hyperprogression in patients with lung cancer treated with immune checkpoint inhibitors.
Published date:
05/19/2021
Excerpt:
Pts with NSCLC treated with ICIs...98 of 427 pts (23%)had HP and an additional 86 pts (20%) had progressive disease...By tumor gene alterations, HP was seen in pts with: EGFR (20/60), STK11/LKB1 (16/25); and MDM2/4 (4/7).
DOI:
10.1200/JCO.2021.39.15_suppl.9105
